CD8A and neoplasm: Consistent with a key role of CD8+ T cells in the observed antitumor effects of combined aPD1 and UNG knockdown, there was no difference in tumor volumes between shRNActrl alone and those with aPD1 treatment and/or UNG depletion (Figure 9, E and F).